Takeda Korea General Manager Moon Hee-seok, who has overseen the company’s growth for over a decade, will step down from his leadership role at the end of this month.

Moon graduated from Chung-Ang University College of Pharmacy and earned a master's degree in business administration from Sogang University. With over 35 years of experience in sales and marketing across multiple pharmaceutical companies, he has developed expertise in a wide range of therapeutic areas.

As the first GM of Shire Pharma Korea, he successfully led the company's growth and organizational integration, focusing on various therapeutic areas, including oncology, rare diseases, and gastrointestinal diseases.

Since 2019, as the general manager of integrated Takeda Korea, he has focused on restructuring the business to focus on specialty care in line with the company's global strategy. This resulted in the successful launch of several innovative therapies in Korea, including Zejula, Livtencity, and Obizur, as well as the strengthened market presence of Adynovate and Alunbrig, expanding treatment options for Korean patients.

Under Moon's leadership, Takeda Korea fostered a horizontal organizational culture, earning recognition as a "Top Employer" for eight consecutive years and a "Great Place to Work" for two consecutive years.This employee-centered, inclusive corporate culture and high-performance collaborative environment have helped strengthen the company's long-term competitiveness.

Moon also chaired the Korea Japanese Pharmaceutical Association (KJPA), promoting collaboration among pharmaceutical companies and contributing to the growth of Korea’s pharmaceutical and bio-industry, Takeda Korea said.

“It is thanks to the dedication and passion of our employees that we have been able to achieve positive results through various challenges while leading Takeda Korea,” Moon said in his retirement message. “I wish Takeda Korea to continue to provide better treatment options for patients in a changing global environment and to continue to lead innovation in the specialty pharmaceutical market.”

Mahender Nayak, Takeda Pharmaceuticals’ Senior Vice President for Growth & Emerging Market, said, “Under GM Moon’s caring leadership, Takeda Korea has grown steadily in innovative medicines and realized patient-centered innovation. We are deeply grateful for his dedication and hard work and wish him continued success and progress in his new journey.”